137 related articles for article (PubMed ID: 17214855)
41. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF
Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453
[TBL] [Abstract][Full Text] [Related]
42. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
[TBL] [Abstract][Full Text] [Related]
43. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
Giltnane JM; Murren JR; Rimm DL; King BL
Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
[TBL] [Abstract][Full Text] [Related]
44. Detection of HER-2/neu (c-erbB-2) overexpression and amplification in breast carcinomas with ambiguous immunohistochemical results. A further contribution to defining the role of fluorescent in situ hybridization.
Sidoni A; Ferri I; Cavaliere A; Bellezza G; Scheibel M; Bucciarelli E
Anticancer Res; 2006; 26(3B):2333-7. PubMed ID: 16821612
[TBL] [Abstract][Full Text] [Related]
45. Limited clinical benefit from trastuzumab in recurrent endometrial cancer: two case reports.
Vandenput I; Vanden Bempt I; Leunen K; Neven P; Berteloot P; Moerman P; Vergote I; Amant F
Gynecol Obstet Invest; 2009; 67(1):46-8. PubMed ID: 18843183
[TBL] [Abstract][Full Text] [Related]
46. A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma.
Choi DH; Shin DB; Lee MH; Lee DW; Dhandapani D; Carter D; King BL; Haffty BG
Cancer; 2003 Oct; 98(8):1587-95. PubMed ID: 14534873
[TBL] [Abstract][Full Text] [Related]
47. A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab.
Tsutani Y; Ohsumi S; Aogi K; Taira N; Kataoka M; Hamamoto Y; Nishimura R; Takashima S
Breast Cancer; 2006; 13(4):374-7. PubMed ID: 17146166
[TBL] [Abstract][Full Text] [Related]
48. Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma.
Xian ZH; Zhang SH; Cong WM; Wu WQ; Wu MC
J Clin Pathol; 2005 May; 58(5):500-3. PubMed ID: 15858121
[TBL] [Abstract][Full Text] [Related]
49. Concordance Between FISH Analysis of Her-2/Neu Gene in Breast Duct Carcinoma and Corresponding Axillary Nodal Metastases: Egyptian National Cancer Institute Experience.
Badawy OM; Hassan H; ELBakey HA; Mosaad M
Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):295-300. PubMed ID: 29750667
[TBL] [Abstract][Full Text] [Related]
50. Salivary duct carcinoma of the parotid gland: is adjuvant HER-2-targeted therapy required?
Lee JS; Kwon OJ; Park JJ; Seo JH
J Oral Maxillofac Surg; 2014 May; 72(5):1023-31. PubMed ID: 24480767
[TBL] [Abstract][Full Text] [Related]
51. Malignant eccrine spiradenoma.
Mirza I; Kloss R; Sieber SC
Arch Pathol Lab Med; 2002 May; 126(5):591-4. PubMed ID: 11958666
[TBL] [Abstract][Full Text] [Related]
52. Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response?
Thor A
J Natl Cancer Inst; 2001 Aug; 93(15):1120-1. PubMed ID: 11481375
[No Abstract] [Full Text] [Related]
53. [Hidradenocarcinoma of the heel associated with inguinal metastases].
Labbardi W; Hali F; Marnissi F; Cribier B; Chiheb S
Ann Dermatol Venereol; 2017; 144(8-9):536-542. PubMed ID: 28528731
[TBL] [Abstract][Full Text] [Related]
54. Atypical and malignant hidradenomas: a histological and immunohistochemical study.
Nazarian RM; Kapur P; Rakheja D; Piris A; Duncan LM; Mihm MC; Hoang MP
Mod Pathol; 2009 Apr; 22(4):600-10. PubMed ID: 19252473
[TBL] [Abstract][Full Text] [Related]
55. Giant apocrine hidradenoma of the breast.
Knoedler D; Susnik B; Gonyo MB; Osipov V
Breast J; 2007; 13(1):91-3. PubMed ID: 17214802
[TBL] [Abstract][Full Text] [Related]
56. Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. Report of two cases.
Roncaroli F; Nosé V; Scheithauer BW; Kovacs K; Horvath E; Young WF; Lloyd RV; Bishop MC; Hsi B; Fletcher JA
J Neurosurg; 2003 Aug; 99(2):402-8. PubMed ID: 12924717
[TBL] [Abstract][Full Text] [Related]
57. Giant hidradenocarcinoma: a report of malignant transformation from nodular hidradenoma.
Lim SC; Lee MJ; Lee MS; Kee KH; Suh CH
Pathol Int; 1998 Oct; 48(10):818-23. PubMed ID: 9788267
[TBL] [Abstract][Full Text] [Related]
58. Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors.
Azzoni C; Bottarelli L; Cecchini S; Lagrasta C; Pizzi S; D'Adda T; Tamburini E; Rindi G; Bordi C
Virchows Arch; 2011 May; 458(5):525-36. PubMed ID: 21445634
[TBL] [Abstract][Full Text] [Related]
59. Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature.
Krishnamurthy J; Krishnamurty DM; Baker JJ; Zhen W; Lydiatt D; Ganti AK
Head Neck; 2013 Dec; 35(12):E372-5. PubMed ID: 23765450
[TBL] [Abstract][Full Text] [Related]
60. Cutaneous apocrine carcinoma in groin with bilateral lymph node metastasis: a case report and review of the literature.
Guo J; Wu G; Xu J; Ma Z; Zhou Z
Int J Clin Exp Pathol; 2014; 7(11):8266-70. PubMed ID: 25550884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
